Global Women’s Health Therapeutics Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

In this report, the Women’s Health Therapeutics Market has been segmented by Drug, Therapeutic Area, Indication, Distribution Channel, and Geography.

Women’s Health Therapeutics Market, Segmentation by Drug

The Women’s Health Therapeutics Market has been segmented by Drug into Actonel, Yaz, Yasmin, Yasminelle, Forteo, Minastrin 24 Fe, Mirena, Nuvaring, Ortho Tri-Cy Lo, Premarin, Prolia, Reclast/Aclasta, Xgeva, Zometa and Others.

Actonel

Actonel holds a significant position in the women’s health therapeutics market, accounting for approximately 10% of total revenue. This bisphosphonate medication is widely used for treating osteoporosis and osteopenia, supporting bone health in postmenopausal women.

Yaz, Yasmin, and Yasminelle

Combined, these oral contraceptives represent about 15% of the market, offering hormonal regulation for contraception and treatment of acne and premenstrual dysphoric disorder (PMDD). Their popularity stems from efficacy and convenient dosing.

Forteo

Forteo contributes nearly 8% of the market, recognized for its anabolic effect in treating osteoporosis. It is favored for patients at high risk of fractures, supporting bone regeneration and increased bone density.

Minastrin 24 Fe

Minastrin 24 Fe holds approximately 5% of the market, offering oral contraceptive benefits and treatment for menstrual disorders. Its low-dose formulation and iron supplementation support patient adherence and overall health.

Mirena

Mirena accounts for around 12% of total revenue, serving as a long-acting reversible contraceptive (LARC) that provides hormonal birth control and treatment for heavy menstrual bleeding. Its convenience and high efficacy contribute to strong adoption.

Nuvaring

Nuvaring contributes about 7% of the market, offering a vaginal ring contraceptive that provides continuous hormone release and improved patient compliance compared to daily pills.

Ortho Tri-Cy Lo

Ortho Tri-Cy Lo holds approximately 4% of the market, recognized for its triphasic hormonal contraception and menstrual regulation. Its tailored hormone dosing reduces side effects and supports cycle control.

Premarin

Premarin contributes around 6% of the market, primarily used in hormone replacement therapy (HRT) to manage menopausal symptoms. It supports bone health and reduces vasomotor symptoms.

Prolia, Reclast/Aclasta, Xgeva, Zometa

These drugs collectively represent about 20% of total revenue, offering treatments for osteoporosis and bone metastases. They include monoclonal antibodies and bisphosphonates that enhance bone density and reduce fracture risk in postmenopausal women.

Others

The 'Others' category accounts for nearly 13% of the market, encompassing additional contraceptives, hormonal therapies, and emerging treatments for women’s health conditions. Ongoing research and clinical advancements are expanding opportunities in this segment.

Women’s Health Therapeutics Market, Segmentation by Therapeutic Area

The Women’s Health Therapeutics Market has been segmented by Therapeutic Area into Hormone Therapies, Contraceptives, Reproductive Health Drugs, and others.

Hormone Therapies

Hormone therapies dominate the women’s health therapeutics market, accounting for approximately 40% of total revenue. These therapies include hormone replacement treatments (HRT) for menopausal symptoms, osteoporosis management, and endometriosis treatment. Rising awareness of postmenopausal health issues and increasing adoption of personalized therapies are fueling growth in this segment.

Contraceptives

Contraceptives represent about 35% of the market, covering a wide range of options including oral pills, intrauterine devices (IUDs), injectables, and vaginal rings. Growing emphasis on family planning, reducing unplanned pregnancies, and women’s reproductive autonomy supports demand for contraceptive therapies.

Reproductive Health Drugs

Reproductive health drugs contribute nearly 15% of total revenue, focusing on treatments for infertility, polycystic ovary syndrome (PCOS), and ovarian stimulation. The rising demand for assisted reproductive technologies (ART) and advancements in fertility medications are driving this segment.

Others

The 'Others' category accounts for approximately 10% of the market, including treatments for osteoporosis, urinary tract infections (UTIs), and cervical dysplasia. Ongoing research and emerging biologic therapies are expanding therapeutic options in this segment.

Women’s Health Therapeutics Market, Segmentation by Indication

The Women’s Health Therapeutics Market has been segmented by Indication into Menopause, Contraception, Hormone-Related Cancers, and Reproductive Disorders.

Menopause

Menopause-related treatments dominate the women’s health therapeutics market, accounting for approximately 35% of total revenue. This segment includes hormone replacement therapies (HRT) for managing vasomotor symptoms, osteoporosis, and urogenital atrophy. Rising awareness of menopausal health and increased adoption of personalized HRT options are fueling growth.

Contraception

Contraception represents about 30% of the market, driven by the growing use of oral contraceptives, intrauterine devices (IUDs), and long-acting reversible contraceptives (LARCs). Focus on family planning and reproductive autonomy supports the demand for a variety of contraceptive options.

Hormone-Related Cancers

Hormone-related cancers contribute nearly 20% of total revenue, covering therapies for breast cancer, ovarian cancer, and endometrial cancer. Increased focus on targeted therapies, precision medicine, and early detection are driving growth in this segment.

Reproductive Disorders

Reproductive disorders account for approximately 15% of the market, focusing on conditions such as polycystic ovary syndrome (PCOS), infertility, and endometriosis. Advancements in fertility treatments and rising demand for assisted reproductive technologies (ART) support growth in this segment.

Women’s Health Therapeutics Market, Segmentation by Distribution Channel

The Women’s Health Therapeutics Market has been segmented by IDistribution Channel into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy.

Hospital Pharmacy

Hospital pharmacies lead the women’s health therapeutics market, accounting for approximately 50% of total revenue. These outlets provide specialized treatments for hormone-related conditions, menopause management, and cancer therapies. The presence of trained healthcare professionals and emphasis on patient safety drive growth in this segment.

Retail Pharmacy

Retail pharmacies represent about 30% of the market, offering easy access to contraceptives, hormonal therapies, and osteoporosis treatments. Convenience, in-store promotions, and the availability of pharmacist consultations support segment growth, especially for self-managed therapies.

Online Pharmacy

Online pharmacies account for approximately 20% of total revenue, reflecting growing consumer preference for home delivery and remote healthcare solutions. Integration of e-prescription services, expanding product range, and rising awareness of digital health platforms are fueling growth in this segment.

Women’s Health Therapeutics Market, Segmentation by Geography

In this report, the Women’s Health Therapeutics Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Women’s Health Therapeutics Market Share (%), by Geographical Region

North America

North America leads the women’s health therapeutics market, accounting for approximately 40% of total revenue. The region benefits from strong healthcare infrastructure, high awareness of women’s health issues, and extensive availability of hormone therapies, contraceptives, and cancer treatments. The presence of major pharmaceutical players and supportive regulatory frameworks drive growth.

Europe

Europe represents nearly 25% of the market, supported by robust screening programs, widespread access to reproductive health services, and strong adoption of personalized medicine. Countries like Germany, the UK, and France are key contributors, driven by rising focus on women’s wellness and advanced treatment options.

Asia Pacific

Asia Pacific holds about 20% of the global market, fueled by increasing healthcare investment, rising awareness of women’s health conditions, and expanding access to innovative therapies in countries like China, Japan, and India. The growing prevalence of chronic conditions and rising disposable incomes support market expansion.

Middle East and Africa

The Middle East and Africa contribute approximately 8% of the market, with growth driven by improving healthcare infrastructure, increasing focus on maternal and reproductive health, and gradual adoption of modern therapeutic options in markets like Saudi Arabia, South Africa, and the UAE.

Latin America

Latin America accounts for nearly 7% of total revenue, with Brazil, Mexico, and Argentina emerging as key markets. Growth is fueled by rising awareness of female-specific conditions, expanding healthcare access, and increasing adoption of advanced therapeutics for women’s health.